Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS — Stella
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
(31 sites) Austria
Innsbruck Medical University, Innsbruck Ordensklinikum Linz, Linz Medical University of Vienna, Vienna Germany
Universitätsklinikum Hamburg - Eppendorf, Hamburg Klinikum rechts der Isar (MRI) der Technischen Universität München Department of Internal Medicine III (Hematology/Oncology) Munchen, München Greece
University Hospital of Alexandroupolis, Alexandroupoli Alexandra General Hospital -Department of Clinical Therapeutics N.K. Univ. of Athens, Athens St Savvas Cancer Hospital, Athens Theagenion Cancer Hospital, Thessaloniki Italy
AOU Ospedali Riuniti di Ancona, Ancona ASST Papa Giovanni XXIII Hospital, Bergamo A.O.U. di Bologna - Policlinico S. Orsola Malpighi, Bologna A.O.Spedali Civili di Brescia, Brescia A.O.U. Careggi - Firenze, Florence A.O.U. Policlinico S. Martino - Ematologia, Genova Policlinico S. Matteo Fondazione IRCCS - Pavia, Pavia AUSL-IRCCS di Reggio Emilia Arcispedale S. Maria Nuova, Reggio Emilia Ospedale "Infermi" di Rimini, Rimini Ematologia IRCCS Casa Sollievo della Sofferenza San Giovanni Rotondo, San Giovanni Rotondo A.O. S. Santa Maria Hospital Institute of Oncohematology Terni, Terni A.O.U. Città della Salute e della Scienza di Torino - SC Ematologia U, Torino
Netherlands
Amsterdam Medical Center, Amsterdam University Medical Center Groningen, Groningen Dijklander ziekenhuis, Purmerend Erasmus University Medical Center Rotterdam, Rotterdam Maasstad Ziekenhuis, Rotterdam
Ospedale S. Maria della Misericordia di Udine, Udine
Age range
18 Years – 70 Years